ke jiang

Ke worked as the group leader/PI to develop Innovative radioligand drug delivery platform technology to address unmet clinical needs and accelerate the discovery, development, and clinical use of radiopharmaceuticals. We are trying to utilize science to solve clinical needs, allowing patients and their families to live a wonderful life with us

I moved to Stanford University to further my research from Switzerland. Here, I am working on imaging probes development for tumor diagnosis, including PET, MRI and fluorescent probes. The major work here is to develop an intra-celluar activated nano platform for their preclinical imaging applications.

The work in Switzerland focused on two parts: one is about synthesis, modification and evaluation of glutamate transporter inhibitors; secondly is about fluorescence labelling of ATP derivatives for protein dynamic investigation and for drug affinity study with the help of single molecular microscopy. We first obtained fluorescent agonist against xx protein. The results are collected and will submit for publish soon.

In Singapore, I worked in a Structural Biology group, where focused on water transporter investigation. My job is to screen small molecule and modify lead compounds to get "promising" drug for their use in water transporter inhibition. In the mean time, I worked on organocatalysis in the group of Prof. Dr. Robin Chi for NHC catalysis investigation, there, I studied a lot of knowledge in the field of catalytic methodology and hope to translate these into biological study, as the first NHC catalyst was found in the biological system.

I finished my master study in China, then I moved to University of Bremen, Germany, which is one of the seven elite universities in Germany. In Germany, I researched on Boron Neutron Capture Therapy for cancer and also focused on lipidation of iron sulphur cluster for their use in enzyme catalysis. Simply speaking, what I did there is to specific deliver boron cluster to tumor sites for thereafter radiation therapy and also to synthesise and modify lead compounds for BBB penetration study.

In Germany, I started my research career in the field of medicinal chemistry. Here, I first focused on total synthesis lipidation of iron sulfur protein for abiogenesis study and their application in bio-energy catalysis. Then I moved to investigate cancer therapy using boron-containing compounds, which holds potentials for cancer therapy through versatile therapeutic mechanism.